Indegene Ltd

Indegene Ltd Share Price Today: Live Updates & Key Insights

Get insights on Indegene Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Indegene Ltd Share Price Chart

Indegene Ltd Fundamentals

Traded Volume: 2,07,771

Market Cap(Cr): 12,248

Avg Traded Price 509.82

1 Year return -20.42%

Upper Circuit 513.6

Lower Circuit 506.5

P/E TTM 27.00

P/B Ratio 19.00

Traded Value(Cr) 1059.74

EPS TTM 18.569

Book value 18.569

Dividend 0.00%

Indegene Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Indegene Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Indegene Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -0.77%

1M -8.40%

3M -11.97%

1Y -20.42%

YTD -15.11%

Indegene Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Indegene Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 1.60L

Day Before Yesterday 2.52L

1W Avg 1.95L

1M Avg 2.43L

3M Avg 3.42L

Indegene Ltd Technical Details

Indegene Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 507

Support 2 503

Support 3 499

Pivot Point : 510

Resistance 1 514

Resistance 2 517

Resistance 3 521

Indegene Ltd Corporate Actions

Indegene Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Indegene Ltd’s capital allocation strategies.

All

Ex-Date 13-Jun-2025 Type D Description 2.00/share@100.00% Record Date 13-Jun-2025 Ratio 100.00

Dividends

Announcement Date 13-Jun-2025 Ex Dividend Date 13-Jun-2025 Dividend(%) 100

Bonus

No Bonus has been declared by INDGN

Splits

No Split has been declared by INDGN

Others

Rights No Rights has been declared by INDGN

Indegene Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Indegene Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Indegene Ltd's relative performance and valuation against major competitors.

Stock Name Inventurus Knowledge Solutions Ltd ₹1568.00 (-1.41%) M. Cap (Cr) 269.17 1 Yr Return (%) NaN% P/E (TTM) 44.12 PB Ratio 23.23

Stock Name Dr Lal Pathlabs Ltd ₹3142.20 (+0.47%) M. Cap (Cr) 263.24 1 Yr Return (%) +3.84% P/E (TTM) 49.25 PB Ratio 13.15

Stock Name Indegene Ltd ₹510.05 (-0.98%) M. Cap (Cr) 122.48 1 Yr Return (%) -20.42% P/E (TTM) 27.47 PB Ratio 5.19

Stock Name Vijaya Diagnostic Centre Ltd ₹1007.40 (-0.40%) M. Cap (Cr) 103.49 1 Yr Return (%) -12.24% P/E (TTM) 68.35 PB Ratio 14.28

Stock Name Metropolis Healthcare Ltd ₹1955.10 (-0.22%) M. Cap (Cr) 101.32 1 Yr Return (%) -3.01% P/E (TTM) 64.03 PB Ratio 8.56

Stock Name Thyrocare Technologies Ltd ₹1535.20 (+0.66%) M. Cap (Cr) 81.45 1 Yr Return (%) +58.32% P/E (TTM) 63.77 PB Ratio 16.68

Stock Name Kovai Medical Center & Hospital Ltd ₹2576.65 (-2.28%) M. Cap (Cr) 28.19 1 Yr Return (%) +68.20% P/E (TTM) 28.66 PB Ratio 6.03

Indegene Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Indegene Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 129.00 Mar 2024 176.20 Mar 2023 81.90 Mar 2022 38.20 Mar 2021 54.60

PARTICULARS Investing Activities Mar 2025 -824.70 Mar 2024 -187.70 Mar 2023 -47.90 Mar 2022 -266.70 Mar 2021 -34.00

PARTICULARS Financing Activities Mar 2025 717.30 Mar 2024 -15.80 Mar 2023 -16.90 Mar 2022 244.90 Mar 2021 -35.50

PARTICULARS Net Cash Flow Mar 2025 22.00 Mar 2024 -28.60 Mar 2023 14.00 Mar 2022 16.20 Mar 2021 -17.90

Indegene Ltd Shareholding Pattern

This shows the ownership breakdown of Indegene Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 0%

Public 81.74%

Other Institutions 3.88%

FII 11.3%

Mutual Funds 3.07%

About Indegene Ltd

Indegene Limited was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to `Indegene Private Limited' and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to `Indegene Limited' on November 17, 2022.The Company is a digital-first life sciences commercialization company, enabling biopharmaceutical, emerging biotech, and medical device companies to develop, launch, and scale the impact of their products with greater speed, precision, and efficiency. As a specialized company, it combine healthcare domain expertise, fit-for-purpose technology, and an agile operating model to solve the most complex problems in the healthcare industry.Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a digital first approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analytics in helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.The Company acquired Cult Health, a full-service healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.The Company launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform in 2023. The Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.In 2024, the Company acquired a controlling stake in Trilogy Writing & Consulting GmbH, a medical writing consultancy firm. It set up a new global delivery center in Hyderabad. In FY 2025, the Company launched a new center in Hyderabad to strengthen the business operations. In Europe, it launched a new entity in Spain and a new center in London. Indegene's Europe-based clients became as a strategic hub for consulting and commercialization solutions and modernize their operations with an AI-first approach. Further, the Company acquired MJL, a UK-based specialized healthcare advertising and communications agency. It launched Cortex, a fit-for-purpose Generative AI platform for the life sciences industry.

Chairman & Executive Director

Manish Gupta

Registered office Aspen Block G4 3rd Flr Manyata, Embassy Busi. Park Nagawara, Bengaluru, Karnataka, 560045

FAX :91-80-4674 4567/+91-80-4644 7777

Background

Incorporation Year 1998

Face Value ₹2.00

Market Lot 1

Indegene Ltd Latest News

VIEW MORE NEWS

FAQs on Indegene Ltd